| Metric | Q3 FY26 | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Total income | 14.8 | 13.7 | 10.0 |
| Net profit | 0.3 | 0.1 | -0.0 |
| Operating margin | 3.4% | 0.7% | 3.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, quarter on quarter | +200.00% |
|---|
BSE results filing, NSE: SHIVMED. Figures extracted from the filing.
Bandaram Pharma Packtech Ltd: key numbers
- Share price
- ₹19.94
- Market cap
- ₹35.84 Cr
- Revenue (annual)
- ₹62.92 Cr
- Net profit (annual)
- ₹1.01 Cr
- P/E (TTM)
- 35.3×Sector 56.3×
- Promoter holding
- 62.66%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Bandaram Pharma Packtech Ltd
All →Bandaram Pharma Packtech Board Meeting Date
Bandaram Pharma Packtech has scheduled a board meeting on 30.09.2026 to consider a proposal for a scheme of arrangement or amalgamation.
Bandaram Pharma Packtech Annual General Meeting
Bandaram Pharma Packtech Limited held its Annual General Meeting on September 24, 2026, approving financial statements and re-appointing auditors and directors.
Bandaram Pharma Packtech Annual General Meeting
Bandaram Pharma Packtech submitted its Annual Report and notice for the AGM, which is now rescheduled for September 24, 2026.
Bandaram Pharma Packtech Management Change
Bandaram Pharma Packtech re-appointed its statutory auditor for 36 months and an independent director for a 60-month term, both approved in the board meeting.
Bandaram Pharma Packtech Q1 FY27 Results: Net Profit ₹0.7 Cr, Up 600.0% QoQ
Bandaram Pharma Packtech Ltd reported revenue from operations of ₹24 Cr (+196.3% YoY) and net profit of ₹0.7 Cr for Q1 FY27.
- Key figure
- Net profit ₹0.7 Cr
Bandaram Pharma Packtech Board Meeting Date
Bandaram Pharma Packtech will hold a board meeting on August 13, 2026, to consider and approve the un-audited financial results for the quarter ended June 30, 2026.